Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.
News|Articles|September 28, 2026
High Value Freight in a Changing Risk Environment.
Author(s)Tucker Company Worldwide
High-value freight is moving through a more complex risk environment. This whitepaper explores how tighter capacity, rising cargo theft severity, freight fraud, and greater liability scrutiny are reshaping transportation strategy. It also outlines a modern approach to carrier assessment, risk-based controls, and balancing capacity with accountability for shippers of critical, high-consequence freight.
Related to this article
FDA this week cleared three new treatments: Lilly's Olumiant for adolescent alopecia areata, AbbVie's Juvmo for Parkinson's disease, and Mirum and Incyte's Atebrioz for the rare bone disorder FOP.
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
Three platform-technology deals paired Nanexa, Earendil Labs, and Atavistik Bio with Novo Nordisk, Genentech, and Roche to advance next-generation metabolic and oncology medicines.
Trending on PharmExec
1
The Legacy of Rutledge: How States and Congress Can Still Regulate Pharmacy Benefit Managers
2
Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz
3
Your Questions Answered: Two FDA Approvals, Six Platform Deals, and a European Warning
4
FDA Approves Welireg Plus Lenvima for Previously Treated Adult Patients With ccRCC
5